As per the latest research findings postulated by the International Dental Association (IDA), the major factors responsible for the occurrence of oral ulcers constant rubbing against misaligned or sharp teeth, accidental biting of the inside of your cheek, poor oral hygiene and burns from eating hot food. Proactive digital marketing strategy to increase consumer awareness worldwide pertaining to the importance of oral health & hygiene and increasing disposable income in low and middle-income countries further propels the oral ulcer drug market growth.
Analgesics are spearheading the drug class market for the oral ulcer drugs market. The growing incidence of canker sores and oral herpes infection across the globe increases the demand for topical analgesics to soothe the pain of the oral mucosal cavity. Corticosteroids will be highlighting exemplary market performance in the near future on account of its anti-inflammatory properties in the treatment of canker sores. The corticosteroids used in drug formulation for the treatment of oral ulcers are Hydrocortisone hemisuccinate, Triamcinolone acetonide, and Betamethasone sodium phosphate.
Browse the full report Oral Ulcer Drug Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027 at https://www.atlanticmarketresearch.com/oral-ulcer-drug-market
Hospital pharmacy is currently leading the distribution channel segment for the oral ulcer drug market. The drugs used in the drug formulations widely employed for the treatment of oral infections are associated with severe side effects hence it needs to be taken under the medical supervision of a hospital pharmacist. Retail pharmacy is expected to highlight sturdy market growth during the forecast period owing to the flourishing personal and consumer care products and the provision of essential medicines at a low price.
North America is representing the largest market share in the geography segment for the oral ulcer drug market. The rising prevalence of oral infection primarily drives the market growth of oral ulcer drugs in the region. According to the latest statistics provided by the Center for Disease Control and Prevention (CDC), approximately 50% of the adult population in the United States are suffering from oral herpes infection. Additionally, the nurturing regulatory environment provided by the USFDA for the sale and distribution of oral ulcer drugs further accentuates the market growth in the region. Europe is placed 2nd in the regional segment for the oral ulcer drug market on account of the favorable reimbursement scenario associated with the medical use of oral ulcer drugs market. The Asia Pacific is anticipated to be the fastest-growing regional segment for oral ulcer drugs market on account of the rising prevalence of oral infection due to poor hygiene, chewing of tobacco, betel nuts, etc., and flourishing personal and consumer healthcare segment.
Pharmaceutical manufacturers actively engaged in the production of oral ulcer drug are Blistex, Inc., 3M Company., Bristol-Myers Squibb Company., GlaxoSmithKline, Plc., Church & Dwight Co, Inc., ECR Pharmaceuticals, Colgate-Palmolive Company, Reckitt Benckiser, Sinclair Pharma and Pfizer, Inc.
Key Market Movements:
- Rising prevalence of oral infection worldwide
- Favorable reimbursement scenario for the medicinal use of oral ulcer drug further propels the market growth
- The nurturing regulatory environment provided for the sale and distribution of oral ulcer drugs further accentuates the market growth